PTC Therapeutics Inc. [NASDAQ: PTCT] gained 1.72% or 0.82 points to close at $48.49 with a heavy trading volume of 1999108 shares. The company report on July 22, 2020 that PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company’s business and outlook on Wednesday, August 5, 2020 at 4:30 p.m. (ET) after the closing of the market.
The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 5897698. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company’s website for 30 days following the call.
It opened the trading session at $47.69, the shares rose to $48.59 and dropped to $47.00, the range by which the price of stock traded the whole day. The daily chart for PTCT points out that the company has recorded -9.77% loss over the past six months. However, it is still -57.49% lower than its most recent low trading price.
If we look at the average trading volume of 712.37K shares, PTCT reached to a volume of 1999108 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about PTC Therapeutics Inc. [PTCT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PTCT shares is $60.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PTCT stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for PTC Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 09, 2020. The new note on the price target was released on February 20, 2020, representing the official price target for PTC Therapeutics Inc. stock. Previously, the target price had yet another raise from $55 to $71, while Citigroup kept a Neutral rating on PTCT stock.
The Average True Range (ATR) for PTC Therapeutics Inc. is set at 2.18, with the Price to Sales ratio for PTCT stock in the period of the last 12 months amounting to 9.80. The Price to Book ratio for the last quarter was 5.72, with the Price to Cash per share for the same quarter was set at 9.17.
Trading performance analysis for PTCT stock
PTC Therapeutics Inc. [PTCT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.15. With this latest performance, PTCT shares dropped by -10.32% in over the last four-week period, additionally sinking by -9.77% over the last 6 months – not to mention a rise of 13.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PTCT stock in for the last two-week period is set at 44.62, with the RSI for the last a single of trading hit 45.23, and the three-weeks RSI is set at 45.97 for PTC Therapeutics Inc. [PTCT]. The present Moving Average for the last 50 days of trading for this stock 51.02, while it was recorded at 47.35 for the last single week of trading, and 48.60 for the last 200 days.
PTC Therapeutics Inc. [PTCT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and PTC Therapeutics Inc. [PTCT] shares currently have an operating margin of -62.80 and a Gross Margin at +87.04. PTC Therapeutics Inc.’s Net Margin is presently recorded at -81.95.
Return on Total Capital for PTCT is now -27.04, given the latest momentum, and Return on Invested Capital for the company is -36.22. Return on Equity for this stock declined to -53.24, with Return on Assets sitting at -18.34. When it comes to the capital structure of this company, PTC Therapeutics Inc. [PTCT] has a Total Debt to Total Equity ratio set at 55.19. Additionally, PTCT Total Debt to Total Capital is recorded at 35.56, with Total Debt to Total Assets ending up at 20.20. Long-Term Debt to Equity for the company is recorded at 50.96, with the Long-Term Debt to Total Capital now at 32.84.
Reflecting on the efficiency of the workforce at the company, PTC Therapeutics Inc. [PTCT] managed to generate an average of -$330,586 per employee. Receivables Turnover for the company is 4.97 with a Total Asset Turnover recorded at a value of 0.22.PTC Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.20.
PTC Therapeutics Inc. [PTCT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, PTC Therapeutics Inc. posted -0.75/share EPS, while the average EPS was predicted by analysts to be reported at -0.58/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -29.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PTCT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for PTC Therapeutics Inc. go to -9.51%.
An analysis of insider ownership at PTC Therapeutics Inc. [PTCT]
There are presently around $3,038 million, or 99.32% of PTCT stock, in the hands of institutional investors. The top three institutional holders of PTCT stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 6,238,168, which is approximately 565.625% of the company’s market cap and around 0.50% of the total institutional ownership; VANGUARD GROUP INC, holding 5,579,171 shares of the stock with an approximate value of $270.53 million in PTCT stocks shares; and FRANKLIN RESOURCES INC, currently with $267.69 million in PTCT stock with ownership of nearly 0.919% of the company’s market capitalization.
Positions in PTC Therapeutics Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 107 institutional holders increased their position in PTC Therapeutics Inc. [NASDAQ:PTCT] by around 14,833,460 shares. Additionally, 105 investors decreased positions by around 10,904,590 shares, while 23 investors held positions by with 36,917,175 shares. The mentioned changes placed institutional holdings at 62,655,225 shares, according to the latest SEC report filing. PTCT stock had 26 new institutional investments in for a total of 1,754,381 shares, while 34 institutional investors sold positions of 3,007,231 shares during the same period.